Valeant Pharmaceuticals

VRX-T

Analysis and Opinions about VRX-T

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
October 12, 2016

It is hard to determine a good entry point. They are repositioning to be an organic grower. She does not have a clear sense of their strategy. There is a lot of goodwill and debt on their balance sheet.

Show full opinionHide full opinion

It is hard to determine a good entry point. They are repositioning to be an organic grower. She does not have a clear sense of their strategy. There is a lot of goodwill and debt on their balance sheet.

COMMENT
COMMENT
October 11, 2016

A real toughie. It has lost a tremendous amount. Looking at the earnings that analysts are projecting, he would probably say it has a 200% upside, which makes it look pretty interesting. The issue is, what is going to happen when they undergo some of those US hearings they have been threatened with? Are they going to escape, or are there going to be massive penalties? The balance sheet is nothing to write home about, as it is full of goodwill. No matter how attractive these companies are, he generally avoids them. They are too risky for his blood.

Show full opinionHide full opinion

A real toughie. It has lost a tremendous amount. Looking at the earnings that analysts are projecting, he would probably say it has a 200% upside, which makes it look pretty interesting. The issue is, what is going to happen when they undergo some of those US hearings they have been threatened with? Are they going to escape, or are there going to be massive penalties? The balance sheet is nothing to write home about, as it is full of goodwill. No matter how attractive these companies are, he generally avoids them. They are too risky for his blood.

COMMENT
COMMENT
October 7, 2016

This is going sideways, but there are still some unanswered questions. An extra cockroach seems to pop out every once in a while. Also, if Hillary gets elected, this company just might have some problems. A high risk situation.

Show full opinionHide full opinion

This is going sideways, but there are still some unanswered questions. An extra cockroach seems to pop out every once in a while. Also, if Hillary gets elected, this company just might have some problems. A high risk situation.

DON'T BUY
DON'T BUY
October 6, 2016

When there are really popular stories that are headline grabbers on both sides of the border, you need to step back. It is going to take a long time for serious money to come back to this name. He doesn’t see what the catalyst is to get the cloud away from the name.

Show full opinionHide full opinion

When there are really popular stories that are headline grabbers on both sides of the border, you need to step back. It is going to take a long time for serious money to come back to this name. He doesn’t see what the catalyst is to get the cloud away from the name.

PAST TOP PICK
PAST TOP PICK
October 4, 2016

(An update from Jerome!) (A Top Pick Feb 8/16.) Short. (A Pairs trade with a Long on Mylan- MYL-Q). It went down about 50% in one day, and he figures it doesn’t get better than that, so he covered this at $50 on March 15/16.

Show full opinionHide full opinion

(An update from Jerome!) (A Top Pick Feb 8/16.) Short. (A Pairs trade with a Long on Mylan- MYL-Q). It went down about 50% in one day, and he figures it doesn’t get better than that, so he covered this at $50 on March 15/16.

COMMENT
COMMENT
September 27, 2016

Had owned this, but sold it when it got near its highs. He would be nervous about this now. It has big litigation risks, and has become the poster child for all sorts of things that it may or may not be guilty of.

Show full opinionHide full opinion

Had owned this, but sold it when it got near its highs. He would be nervous about this now. It has big litigation risks, and has become the poster child for all sorts of things that it may or may not be guilty of.

COMMENT
COMMENT
September 22, 2016

On the way up, people kept asking about this stock all the time. He was always dubious because when a company is doing so many takeovers, often they get into trouble. They have about $30 billion in debt with about $40 billion in Goodwill and intangibles. That is going to lead to a lot of write-downs. They have problems with government regulations, legal problems, huge debt load and certain morality issues. He can see this possibly going bankrupt.

Show full opinionHide full opinion

On the way up, people kept asking about this stock all the time. He was always dubious because when a company is doing so many takeovers, often they get into trouble. They have about $30 billion in debt with about $40 billion in Goodwill and intangibles. That is going to lead to a lot of write-downs. They have problems with government regulations, legal problems, huge debt load and certain morality issues. He can see this possibly going bankrupt.

SELL
SELL
September 20, 2016

At the time, this was a compelling pitch. You were buying drugs that were mispriced and were making a lot of money. It is really difficult when looking at a highly leveraged company like this to justify a turnaround. They are going to have to reduce debt and sell off some assets. In the meantime, the regulatory environment is not very favourable at all.

Show full opinionHide full opinion

At the time, this was a compelling pitch. You were buying drugs that were mispriced and were making a lot of money. It is really difficult when looking at a highly leveraged company like this to justify a turnaround. They are going to have to reduce debt and sell off some assets. In the meantime, the regulatory environment is not very favourable at all.

DON'T BUY
DON'T BUY
September 16, 2016

The stock made a very, very significant top in 2015, and he is not sure that we have seen the bottom. Prices are hovering around the lows, which means sellers are persistent, and strong buyers have not emerged. He wouldn’t touch this with an 11-foot pole.

Show full opinionHide full opinion

The stock made a very, very significant top in 2015, and he is not sure that we have seen the bottom. Prices are hovering around the lows, which means sellers are persistent, and strong buyers have not emerged. He wouldn’t touch this with an 11-foot pole.

COMMENT
COMMENT
September 1, 2016

(Market Call Minute.) Not interested.

Show full opinionHide full opinion

(Market Call Minute.) Not interested.

COMMENT
COMMENT
August 31, 2016

A company that is attributed with everything that is wrong with the healthcare Index in Canada. It represents an extraordinarily high amount of the healthcare Index at 50% or 60%. Believes they have possibly turned over a new leaf. However, the stock has also been reset. It is possible they can get to $40 which would give a 29%-30% return, but you have to have the stomach for it. 2nd quarter results showed a sequential improvement with earnings per share at $1.40. He would treat this as a trading stock.

Show full opinionHide full opinion

A company that is attributed with everything that is wrong with the healthcare Index in Canada. It represents an extraordinarily high amount of the healthcare Index at 50% or 60%. Believes they have possibly turned over a new leaf. However, the stock has also been reset. It is possible they can get to $40 which would give a 29%-30% return, but you have to have the stomach for it. 2nd quarter results showed a sequential improvement with earnings per share at $1.40. He would treat this as a trading stock.

SELL
SELL
August 29, 2016

(Market Call Minute.) This company has lost all faith of investors. You can’t trust the financial statements.

Show full opinionHide full opinion

(Market Call Minute.) This company has lost all faith of investors. You can’t trust the financial statements.

COMMENT
COMMENT
August 26, 2016

He can only comment on this from a technical perspective, because there are so many things that are changing from the fundamental side and value. Looking at valuations, the stock is cheap trading at 4 or 5 times earnings, but are those earnings accurate? Technically, it looks interesting. Since March it really has traded in a very flat basing pattern. Normally that means it can perform going forward.

Show full opinionHide full opinion

He can only comment on this from a technical perspective, because there are so many things that are changing from the fundamental side and value. Looking at valuations, the stock is cheap trading at 4 or 5 times earnings, but are those earnings accurate? Technically, it looks interesting. Since March it really has traded in a very flat basing pattern. Normally that means it can perform going forward.

COMMENT
COMMENT
August 17, 2016

This is not really overvalued. It is a situation that is trading at distressed levels. There were questions as to whether or not the company was going to run into debt default problems, and whether or not it would manage to stay as a going business. There have been lots of concerns and lots of Short stories against it. This is a rollup company that did its last couple of acquisitions using debt, and ended up with a lot of debt. Had some problems with regards to a related pharmacy distribution company. It is really, really cheap down here, and thinks it is going to slowly recover. To bet against this company at these levels is a tricky thing to do.

Show full opinionHide full opinion

This is not really overvalued. It is a situation that is trading at distressed levels. There were questions as to whether or not the company was going to run into debt default problems, and whether or not it would manage to stay as a going business. There have been lots of concerns and lots of Short stories against it. This is a rollup company that did its last couple of acquisitions using debt, and ended up with a lot of debt. Had some problems with regards to a related pharmacy distribution company. It is really, really cheap down here, and thinks it is going to slowly recover. To bet against this company at these levels is a tricky thing to do.

DON'T BUY
DON'T BUY
August 16, 2016

(Market Call Minute.) She would not be buying this. Very low earnings visibility. They problems in the US are still unresolved.

Show full opinionHide full opinion

(Market Call Minute.) She would not be buying this. Very low earnings visibility. They problems in the US are still unresolved.

Showing 46 to 60 of 714 entries